PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Negative EBIT growth while CRVO is at 22.51%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.64%
Negative operating income growth while CRVO is at 22.51%. Joel Greenblatt would press for urgent turnaround measures.
-15.16%
Negative net income growth while CRVO stands at 8.50%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
2.78%
EPS growth under 50% of CRVO's 100.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
2.78%
Diluted EPS growth under 50% of CRVO's 100.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
19.07%
Slight or no buybacks while CRVO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
19.07%
Slight or no buyback while CRVO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-16.01%
Dividend reduction while CRVO stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-25.31%
Negative OCF growth while CRVO is at 3.29%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-30.01%
Negative FCF growth while CRVO is at 3.29%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2395.20%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
87.33%
OCF/share CAGR of 87.33% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
68.32%
3Y OCF/share CAGR of 68.32% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-1414.90%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.17%
Net income/share CAGR of 92.17% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
80.18%
3Y net income/share CAGR of 80.18% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
1411.37%
Equity/share CAGR of 1411.37% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-77.60%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-28.05%
Negative 3Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
13.37%
Positive BV/share change while CRVO is negative. John Neff sees a clear edge over a competitor losing equity.
-15.85%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
22.47%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-1.59%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.